12,743 Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) Acquired by HighVista Strategies LLC

HighVista Strategies LLC bought a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 12,743 shares of the company’s stock, valued at approximately $603,000.

Other institutional investors also recently bought and sold shares of the company. Values First Advisors Inc. purchased a new stake in shares of Kymera Therapeutics during the 3rd quarter valued at $61,000. Mirae Asset Global Investments Co. Ltd. increased its position in Kymera Therapeutics by 27.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after buying an additional 504 shares in the last quarter. Comerica Bank increased its position in Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after buying an additional 400 shares in the last quarter. Public Employees Retirement Association of Colorado purchased a new stake in Kymera Therapeutics in the second quarter valued at about $139,000. Finally, Quest Partners LLC boosted its holdings in Kymera Therapeutics by 1,402.0% in the second quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock worth $156,000 after acquiring an additional 4,865 shares in the last quarter.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 15.82% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $38.00 to $57.00 in a report on Monday. Oppenheimer raised their price target on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Friday, September 27th. Truist Financial reiterated a “buy” rating and set a $53.00 price objective (down from $54.00) on shares of Kymera Therapeutics in a research note on Friday, November 1st. UBS Group cut their target price on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Finally, Wolfe Research raised Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price target for the company in a research report on Monday, August 26th. Three investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $53.40.

Kymera Therapeutics Stock Up 1.9 %

Kymera Therapeutics stock opened at $47.74 on Tuesday. The business’s 50-day moving average price is $46.82 and its 200 day moving average price is $42.26. The firm has a market cap of $3.09 billion, a price-to-earnings ratio of -20.40 and a beta of 2.16. Kymera Therapeutics, Inc. has a 52 week low of $20.32 and a 52 week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $3.74 million for the quarter, compared to analysts’ expectations of $10.34 million. During the same quarter last year, the company earned ($0.90) EPS. The business’s revenue was down 20.9% on a year-over-year basis. Equities analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.